CTOs on the Move

EpicentRx Inc

www.epicentrx.com

 
EpicentRx is a patient-driven immuno-oncology company with minimally toxic therapies that work across diverse patient populations and tumor types for the best possible quality of life during treatment.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.epicentrx.com
  • 11099 North Torrey Pines Road Suite 160
    La Jolla, CA USA 92037
  • Phone: 858.947.6635

Executives

Name Title Contact Details

Funding

EpicentRx Inc raised $35M on 11/13/2019

Similar Companies

180 Life Sciences

Leading Research into Solving one of the World`s Largest Drivers of Disease: Inflammation

Hamilton

The leader in liquid handling equipment and laboratory automation technology, Hamilton Robotics is recognized for advancing life science and biotechnology industries with products that offer reliability, performance and flexibility. Hamilton is the ind...

Artemisia BioMedical

Artemisia BioMedical is a Renton, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Xcell Biosciences

Xcell Bio is a San Francisco-based life science company dedicated to bringing an innovative primary cell control solution to the immunotherapy market to support research, drug discovery, and cell manufacturing. Xcell`s mission is to democratize maintenance, expansion and control of any primary cell type through its bench-top primary cell control systems, reagent kits, software, and standardized protocols. The technology delivers simple control of primary cell types from blood or solid tissue, including a range of immune cells, stem cells, and tumor cells. This patient-centric technology offers a unique and proprietary capability to improve immunotherapy efficacy, safety, and persistence through more predictive and iterative therapy development and rapid, highly-controlled clinical cell manufacturing.

Color

Color`s mission is to help people lead the healthiest lives that science and medicine can offer. We launched in April 2015 with a simple, affordable genetic test to help people understand their risk for hereditary cancer. In 2017, we added coverage for hereditary heart conditions.